Get the Stockscreener App
164.17
5.62%
8.73
After Hours:
164.17
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $164.17, with a volume of 2.55M.
It is up +5.62% in the last 24 hours and up +8.74% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$155.44
Open:
$154
24h Volume:
2.55M
Relative Volume:
3.04
Market Cap:
$18.32B
Revenue:
$9.54B
Net Income/Loss:
$841.00M
P/E Ratio:
22.07
EPS:
7.44
Net Cash Flow:
$1.02B
1W Performance:
+8.11%
1M Performance:
+8.74%
6M Performance:
+14.89%
1Y Performance:
+27.43%
1-Day Range:
$153.99
$167.08
1-Week Range:
$150.99
$167.08
52-Week Range:
$123.04
$167.08
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
164.17 | 18.32B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
606.74 | 232.08B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
223.08 | 160.42B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
151.38 | 42.01B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
201.78 | 36.62B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
423.99 | 34.72B | 3.84B | 866.24M | 792.60M | 10.37 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Quest Diagnostics (NYSE:DGX) Upgraded by StockNews.com to Buy Rating - MarketBeat
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics Dominates Healthcare Rankings in Fortune's Elite ListHere's Why It Matters - StockTitan
Why Quest Diagnostics Stock Was Blasting Higher Today - Yahoo Finance
Quest Diagnostics Stock Hits Over 2-Month High On Q4 Beat, Dividend Hike: Retail Cheer Grows - MSN
Jefferies Raises Price Target on Quest Diagnostics to $190 From $185 -January 30, 2025 at 02:20 pm EST - Marketscreener.com
Quest Diagnostics Delivers Q4 Earnings Beat: The Details - Benzinga
Quest stock jumps 6% on dividend raise, outlook, earnings (DGX:NYSE) - Seeking Alpha
Quest Diagnostics' Stellar Quarter Tops Wall Street Forecasts - Finimize
Quest Diagnostics stock hits 52-week high at $165.58 By Investing.com - Investing.com Canada
Quest Diagnostics stock hits 52-week high at $165.58 - Investing.com
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? - The Motley Fool
Quest Diagnostics (NYSE:DGX) Updates FY 2025 Earnings Guidance - MarketBeat
Quest Diagnostics (DGX) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
Quest Diagnostics: Q4 Earnings Snapshot - San Antonio Express-News
Quest Diagnostics Exceeds Q4 Expectations with EPS of $1.95 and Revenue of $2.62 Billion - GuruFocus.com
Quest Diagnostics Q4 Adjusted Earnings, Net Revenue Increase; 2025 Guidance Issued - Marketscreener.com
Manning & Napier Advisors LLC Sells 2,789 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Earnings Flash (DGX) Quest Diagnostics Posts Q4 Revenue $2.62B, vs. FactSet Est of $2.58B - Marketscreener.com
(DGX) Quest Diagnostics Forecasts Fiscal Year 2025 Revenue Range $10.70B$10.85B - Marketscreener.com
Quest Diagnostics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits - Quantisnow
Quest Diagnostics Delivers Massive Growth: Q4 Revenue Hits $2.62B, Announces Generous Dividend Hike - StockTitan
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Returns At Quest Diagnostics (NYSE:DGX) Appear To Be Weighed Down - Yahoo Finance
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Quest Diagnostics finalizes deal to acquire University Hospitals lab assets - Crain's Cleveland Business
Quest Diagnostics completes University Hospitals asset acquisition - Yahoo! Voices
2,351 Shares in Quest Diagnostics Incorporated (NYSE:DGX) Purchased by BankPlus Wealth Management LLC - MarketBeat
Nisa Investment Advisors LLC Buys 402 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - Defense World
Brighton Jones LLC Invests $323,000 in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest Diagnostics: Good Growth Prospects, But Little To No Upside Left At Current Valuation - Seeking Alpha
Quest Diagnostics Q4 Earnings Preview: What's in Store for the Stock? - MSN
Quest Diagnostics Expands Ohio Presence with University Hospitals Lab Acquisition - StockTitan
Quest Diagnostics Incorporated (NYSE:DGX) Could Be Riskier Than It Looks - Simply Wall St
AEGON ASSET MANAGEMENT UK Plc Increases Holdings in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Merit Financial Group LLC Acquires 696 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - Defense World
Should Value Investors Buy Quest Diagnostics (DGX) Stock? - Yahoo Finance
Red Door Wealth Management LLC Makes New $478,000 Investment in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Quest Diagnostics (DGX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Earnings Preview: What to Expect From Quest Diagnostics' Report - MSN
OhioHealth outsources lab work to Quest Diagnostics - Outsource Accelerator
Quest Diagnostics Incorporated (NYSE:DGX) Holdings Raised by Mitsubishi UFJ Asset Management UK Ltd. - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Shares Acquired by Hennion & Walsh Asset Management Inc. - Defense World
Park Avenue Securities LLC Purchases 955 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - Defense World
Quest Diagnostics Incorporated (NYSE:DGX) Position Boosted by UMB Bank n.a. - MarketBeat
Short Interest in Quest Diagnostics Incorporated (NYSE:DGX) Increases By 6.3% - MarketBeat
9,488 Shares in Quest Diagnostics Incorporated (NYSE:DGX) Bought by Avanza Fonder AB - MarketBeat
DGX (Quest Diagnostics) Operating Income : $1,252 Mil (TTM As of Sep. 2024) - GuruFocus.com
Wedge Capital Management L L P NC Decreases Stock Holdings in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):